StockNews.AI
MRNA
StockNews.AI
3 days

Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE

1. FDA approves mNEXSPIKE vaccine for high-risk adults aged 12 and older. 2. mNEXSPIKE shows 9.3% higher efficacy than Spikevax in older adults. 3. Availability expected for 2025-2026 respiratory virus season in the U.S. 4. Similar safety profile to earlier vaccines, with manageable side effects. 5. Approval expands Moderna's leadership in mRNA vaccine technology.

10 mins saved
Full Article

FAQ

Why Very Bullish?

The FDA approval of mNEXSPIKE significantly enhances Moderna's product lineup, potentially driving revenue growth as new variants or resurgence of COVID-19 may increase demand for vaccines. Historically, each product approval tends to result in a positive stock price reaction, especially in high-need markets.

How important is it?

The article highlights a pivotal regulatory approval that reinforces Moderna's market position and growth potential in an evolving healthcare landscape focused on mRNA technology.

Why Long Term?

The long-term demand for COVID-19 vaccines, combined with upcoming respiratory seasons, positions Moderna favorably for sustained revenue growth. Previous launches of new vaccines and therapies also contributed to long-term stock appreciation.

Related Companies

PFEJNJNVAXBNTX
mNEXSPIKE becomes Moderna's third FDA-approved product Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mNEXSPIKE® (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC).[1]"The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19," said Stéphane Bancel, Chief Executive Officer of Moderna. "COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA's timely review and thank the entire Moderna team for their hard work and continued commitment to public health."The FDA's approval of mNEXSPIKE is based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial (ClinicalTrials.gov Identifier: NCT05815498), which enrolled approximately 11,400 participants aged 12 years and older. The primary efficacy objective in this study was to demonstrate the non-inferior vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared to that after the comparator vaccine, mRNA-1273 (Spikevax®), Moderna's original COVID-19 vaccine. Participants received either a 10 μg dose of mRNA-1283 or a 50 μg dose of mRNA-1273. mRNA-1283 showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older, and in a descriptive sub-group analysis, a 13.5% higher rVE in adults aged 65 and older.In the Phase 3 trial, mRNA-1283 was found to have a similar safety profile to mRNA-1273, with fewer local reactions and comparable systemic reactions. The most commonly solicited side effects were injection site pain, fatigue, headache and myalgia.Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA®, the Company's approved respiratory syncytial virus (RSV) vaccine.mRNA-1283 is under review with regulators in multiple markets around the world.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.mNEXSPIKE®, mRESVIA® and Spikevax®are registered trademarks of Moderna.INDICATION mNEXSPIKE is a vaccine to protect against COVID-19. mNEXSPIKE is for people who have received a COVID-19 vaccine before and are:• 65 years of age and older, or• 12 years through 64 years of age at high risk for severe COVID-19.Vaccination with mNEXSPIKE may not protect all people who receive the vaccine.IMPORTANT SAFETY INFORMATIONYou should not get mNEXSPIKE if you hada severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX (COVID-19 Vaccine, mRNA), or any Moderna COVID-19 vaccine or to any ingredient in these vaccines.What are the risks of mNEXSPIKE?There is a very small chance that mNEXSPIKE could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of mNEXSPIKE. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. Signs of a severe allergic reaction can include:Trouble breathingSwelling of your face and throatA fast heartbeatA rash all over your bodyDizziness and weaknessMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines. Myocarditis and pericarditis following mRNA COVID-19 vaccines have occurred most commonly in males 12 years through 24 years of age. You should seek medical attention right away if you or your child has any of the following symptoms after receiving the vaccine, particularly during the 2 weeks after receiving a dose of the vaccine:Chest painShortness of breathFeelings of having a fast-beating, fluttering, or pounding heartSide effects that have been reported in clinical trials with mNEXSPIKE include:Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection, swelling (hardness), and redness.General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea, vomiting, and feverTell your vaccination provider about all of your medical conditions, including if you:have any allergieshad a severe allergic reaction after receiving a previous dose of any COVID-19 vaccinehave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)have a feverhave a bleeding disorder or are on a blood thinnerare immunocompromised or are on a medicine that affects your immune systemare pregnant or plan to become pregnantare breastfeedinghave received any other COVID-19 vaccinehave ever fainted in association with an injectionThese may not be all the possible side effects of mNEXSPIKE. Ask your healthcare provider about any side effects that concern you. You may report side effects to Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or http://vaers.hhs.gov.Please click for mNEXSPIKE Full Prescribing Information.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the efficacy, safety and tolerability of mNEXSPIKE; and the availability of Moderna's respiratory vaccines for the 2025-2026 season. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.Moderna ContactsMedia:Chris RidleyHead of Global Media Relations+1 617-800-3651[email protected]Investors:Lavina TalukdarSenior Vice President & Head of Investor Relations+1 617-209-5834[email protected][1] https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.htmlSOURCE: Moderna, Inc.

Related News